- Home
- AUTL vs PCRX Comparison
AUTL vs PCRX Comparison
Compare AUTL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | PCRX |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.6M | 1.0B |
| IPO Year | 2018 | 2011 |
Fundamental Metrics
Financial Performance| Metric | AUTL | PCRX |
|---|---|---|
| Price | $1.61 | $26.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.33 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 3.8M | 723.2K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $51,128,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $658.11 | $6.24 |
| Revenue Next Year | $91.34 | $9.53 |
| P/E Ratio | ★ N/A | $55.78 |
| Revenue Growth | ★ 406.67 | 3.14 |
| 52 Week Low | $1.11 | $18.17 |
| 52 Week High | $2.88 | $27.64 |
Technical Indicators
Market Signals| Indicator | AUTL | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.11 | 72.55 |
| Support Level | $1.46 | $23.63 |
| Resistance Level | $1.66 | $24.81 |
| Average True Range (ATR) | 0.10 | 0.93 |
| MACD | 0.03 | 0.25 |
| Stochastic Oscillator | 84.04 | 100.00 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.